As tumor-infiltrating CD4+ or FoxP3+ T cells are associated with poor prognosis in human BCa, this suggested that RANKL inhibition could be used in combination with other therapies to improve outcomes, including with ICIs, which are associated with substantially disparate responses in different tumor types and patients [128]. This evidence concerns the gene CD4 and neoplasm.